Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Industry Group: Pharmaceuticals
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is active in the Chinese healthcare sector. The company manufactures pharmaceutical products including antibiotics, vasodilators, and traditional Chinese medical therapies in preparations such as injection, tablet, capsule, powder, cream, and oral liquid. Its operations are divided into three main segments: pharmaceutical manufacturing, pharmaceutical distribution & retail, and health products. The greater portion of its revenue comes from its pharmaceutical activities in patent medicine, raw materials, distribution, and retail. The rest of its revenues come from its beverage, food, cosmetics, and health products. The company's primary market is China.
ESG Risk Rating
Industry Group (1st = lowest risk)
Pharmaceuticals 677 out of 1028
Global Universe 12847 out of 15120
What are the ESG Risk Ratings?
Notice: The information provided is for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. Usage as a credit rating or as a benchmark is not permitted. Unless otherwise explicitly agreed in writing, usage for products and services, index creation, derivative work, portfolio or fund management, or any other usage are not permitted. By way of exception, usage is permitted only to the rated company, limited to a single reference of its own information in annual reporting and sustainability website, mentioning Sustainalytics as a source.
|Company||ESG Risk Rating||Industry Rank|
|Vifor Pharma AG||
|213 out of 1028|
|458 out of 1028|
|Horizon Therapeutics Plc||
|621 out of 1028|
|Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.||
|677 out of 1028|
|Innovent Biologics, Inc.||
|783 out of 1028|
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.'s Exposure is Medium
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.'s Management of ESG Material Risk is Weak
How do the ESG Risk Ratings work?
Top Material ESG Issues for Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
Highest Controversy level that has impacted Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level